Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
April 22 2021 - 7:28AM
Business Wire
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
pioneering a new approach to treat complex diseases and improve
health using endogenous metabolic modulator (EMM) compositions,
today announced the following upcoming oral presentation at the DDW
2021 regarding AXA1665, the company’s product candidate for the
reduction in risk of recurrent overt hepatic encephalopathy
(OHE):
- Title: A Novel, Precision-Engineered Amino Acid
Composition, AXA1665, is Safe, Well-Tolerated and Improves
Neurocognition and Physical Function in Child-Pugh A and B Subjects
Abstract Number: 848 Presenter: Dr. Arun Sanyal,
Professor in the Virginia Commonwealth University (VCU) Department
of Internal Medicine and Education Core Director in the VCU Center
for Clinical and Translational Research Session: #4450
Portal Hypertension Date/Time: Sunday, May 23rd from
5:45-6:00 p.m. ET
DDW 2021 is being held virtually from May 21 to 23, 2021.
Abstracts are expected to appear on DDW’s website in late April and
in the May online supplement to Gastroenterology. ePosters and
ePapers will be made available on this website during the congress.
DDW is the world’s leading educational forum for clinicians,
researchers, students and trainees working in gastroenterology,
hepatology, GI endoscopy, gastrointestinal surgery and related
fields.
About Endogenous Metabolic Modulators (EMMs)
EMMs are a broad family of naturally occurring molecules,
including amino acids, that regulate human metabolism. Axcella is
developing a range of novel product candidates that are comprised
of multiple EMMs engineered in distinct combinations and ratios to
simultaneously impact multiple metabolic pathways to modify the
underlying causes of various complex diseases and improve
health.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor this portion
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a
new approach to treat complex diseases and improve health using
endogenous metabolic modulator (EMM) compositions. The company’s
product candidates are comprised of EMMs and their derivatives that
are engineered in distinct combinations and ratios to
simultaneously impact multiple biological pathways. Axcella’s
pipeline includes lead therapeutic candidates for non-alcoholic
steatohepatitis (NASH) and the reduction in risk of overt hepatic
encephalopathy (OHE) recurrence. For more information, please visit
www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210422005151/en/
Jason Fredette jfredette@axcellahealth.com 857.320.2236
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024